Panoptes Pharma GmbH
🇦🇹Austria
- Country
- 🇦🇹Austria
- Ownership
- Subsidiary
- Established
- 2013-01-01
- Employees
- 1
- Market Cap
- -
A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- KeratoconjunctivitisOcular Surface Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Panoptes Pharma GmbH
- Target Recruit Count
- 45
- Registration Number
- NCT03769454
- Locations
- 🇦🇹
University Hospital Vienna, Vienna, Austria
A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Panoptes Pharma GmbH
- Target Recruit Count
- 12
- Registration Number
- NCT03634475
- Locations
- 🇧🇪
University Hospital Leuven, Leuven, Belgium
🇩🇪Charité Berlin, Berlin, Germany
🇩🇪LMU Munich, Munich, Germany
© Copyright 2025. All Rights Reserved by MedPath